Q2 2026 saw a 17.2% NAV total return in CHF, net profit of CHF 451 mn, and strong outperformance versus the Nasdaq Biotechnology Index. Twelve new investments and three M&A deals highlighted portfolio activity, while a revised dividend policy targets a 3-5% yield.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.